Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Patent: 8,945,551

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,945,551
Title:Biopolymer hybrid gel-depot delivery system
Abstract: The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.
Inventor(s): Mainwaring; David Edward (North Melbourne, AU), Al Kobaisi; Mohammad (Glen Iris, AU), Chua; Brendon Yew Loong (Mount Waverley, AU), Jackson; David Charles (North Balwyn, AU)
Assignee: Polymers CRC Ltd. (AU)
Application Number:13/382,655
Patent Claims:see list of patent claims

Details for Patent 8,945,551

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 1997-12-10 ⤷  Free Forever Trial 2029-07-09
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 1998-05-12 ⤷  Free Forever Trial 2029-07-09
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 2003-01-02 ⤷  Free Forever Trial 2029-07-09
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Free Forever Trial 2029-07-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.